Citius Oncology (CTOR) Ratios

131 Followers

Citius Oncology Ratios

CTOR's free cash flow for Q2 2026 was $0.80. For the 2026 fiscal year, CTOR's free cash flow was decreased by $ and operating cash flow was $-16.08. See a summary of the company’s cash flow.

Ratios	TTM	Sep 25	Sep 24	Sep 23
Liquidity Ratios
Current Ratio	0.50	0.56	0.34	0.37
Quick Ratio	0.12	0.11	0.08	0.37
Cash Ratio	0.04	0.08	<0.01	<0.01
Solvency Ratio	-0.64	-0.44	-0.55	-0.57
Operating Cash Flow Ratio	-0.29	-0.11	<0.01	-0.03
Short-Term Operating Cash Flow Coverage	0.00	0.00	0.00	0.00
Net Current Asset Value	$ -36.01M	$ -28.53M	$ -27.26M	$ -14.46M
Leverage Ratios
Debt-to-Assets Ratio	0.04	0.04	0.05	0.00
Debt-to-Equity Ratio	0.11	0.08	0.08	0.00
Debt-to-Capital Ratio	0.10	0.08	0.08	0.00
Long-Term Debt-to-Capital Ratio	0.10	0.08	0.08	0.00
Financial Leverage Ratio	2.86	2.25	1.83	1.87
Debt Service Coverage Ratio	-140.25	-112.57	0.00	0.00
Interest Coverage Ratio	-146.59	-107.89	0.00	0.00
Debt to Market Cap	0.06	0.03	0.04	0.00
Interest Debt Per Share	0.04	0.05	0.05	0.00
Net Debt to EBITDA	-0.03	<0.01	-0.18	<0.01
Profitability Margins
Gross Profit Margin	80.07%	0.00%	0.00%	0.00%
EBIT Margin	-742.27%	0.00%	0.00%	0.00%
EBITDA Margin	-732.05%	0.00%	0.00%	0.00%
Operating Profit Margin	-775.60%	0.00%	0.00%	0.00%
Pretax Profit Margin	-747.56%	0.00%	0.00%	0.00%
Net Profit Margin	-757.57%	0.00%	0.00%	0.00%
Continuous Operations Profit Margin	-757.57%	0.00%	0.00%	0.00%
Net Income Per EBT	101.34%	104.46%	102.80%	104.75%
EBT Per EBIT	96.38%	100.77%	100.00%	100.00%
Return on Assets (ROA)	-42.22%	-24.53%	-25.07%	-26.60%
Return on Equity (ROE)	-99.47%	-55.19%	-45.84%	-49.72%
Return on Capital Employed (ROCE)	-103.90%	-45.72%	-39.82%	-45.42%
Return on Invested Capital (ROIC)	-103.90%	-45.72%	-39.82%	-45.42%
Return on Tangible Assets	-143.65%	-24.53%	-25.07%	-164.16%
Earnings Yield	-64.37%	-16.65%	-21.26%	-1.24%
Efficiency Ratios
Receivables Turnover	5.20	0.00	0.00	0.00
Payables Turnover	0.13	0.00	0.00	0.00
Inventory Turnover	0.05	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00
Asset Turnover	0.06	0.00	0.00	0.00
Working Capital Turnover Ratio	-0.30	0.00	0.00	0.00
Cash Conversion Cycle	4.57K	0.00	0.00	0.00
Days of Sales Outstanding	70.19	0.00	0.00	0.00
Days of Inventory Outstanding	7.40K	0.00	0.00	0.00
Days of Payables Outstanding	2.90K	0.00	0.00	0.00
Operating Cycle	7.47K	0.00	0.00	0.00
Cash Flow Ratios
Operating Cash Flow Per Share	-0.17	-0.07	<0.01	>-0.01
Free Cash Flow Per Share	-0.17	-0.07	<0.01	>-0.01
CapEx Per Share	<0.01	<0.01	<0.01	<0.01
Free Cash Flow to Operating Cash Flow	1.00	1.00	1.00	1.00
Dividend Paid and CapEx Coverage Ratio	-1.20M	-1.37M	31.59K	-150.33K
Capital Expenditure Coverage Ratio	-1.20M	-1.37M	31.59K	-150.33K
Operating Cash Flow Coverage Ratio	-4.44	-1.45	0.03	0.00
Operating Cash Flow to Sales Ratio	-3.00	0.00	0.00	0.00
Free Cash Flow Yield	-27.46%	-3.69%	0.13%	-0.06%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	-1.51	-5.97	-4.70	-80.55
Price-to-Sales (P/S) Ratio	11.73	0.00	0.00	0.00
Price-to-Book (P/B) Ratio	2.01	3.32	2.16	40.05
Price-to-Free Cash Flow (P/FCF) Ratio	-3.91	-27.08	787.17	-1.70K
Price-to-Operating Cash Flow Ratio	-4.20	-27.08	787.14	-1.70K
Price-to-Earnings Growth (PEG) Ratio	0.03	-0.45	-0.08	-0.54
Price-to-Fair Value	2.01	3.32	2.16	40.05
Enterprise Value Multiple	-1.63	-6.33	-5.02	-84.37
Enterprise Value	62.55M	148.61M	103.26M	1.02B
EV to EBITDA	-1.52	-6.33	-5.02	-84.37
EV to Sales	11.15	0.00	0.00	0.00
EV to Free Cash Flow	-3.71	-27.06	817.24	-1.70K
EV to Operating Cash Flow	-3.71	-27.06	817.22	-1.70K
Tangible Book Value Per Share	-0.36	0.61	0.64	-0.16
Shareholders’ Equity Per Share	0.35	0.61	0.64	0.29
Tax and Other Ratios
Effective Tax Rate	-0.01	-0.04	-0.03	-0.05
Revenue Per Share	0.06	0.00	0.00	0.00
Net Income Per Share	-0.42	-0.34	-0.30	-0.14
Tax Burden	1.01	1.04	1.03	1.05
Interest Burden	1.01	1.01	1.00	1.00
Research & Development to Revenue	0.73	0.00	0.00	0.00
SG&A to Revenue	7.42	0.00	0.00	0.00
Stock-Based Compensation to Revenue	0.00	0.00	0.00	0.00
Income Quality	0.40	0.22	>-0.01	0.05

Currency in USD